Prospective risk stratification of sudden cardiac death in Marfan's syndrome

详细信息    查看全文

• 作者：Boris A. Hoffmann ; Meike Rybczynski ; Thomas Rostock ; Helge Servatius ; Imke Drewitz ; Daniel Steven ; Ali Aydin ; Sara Sheikhzadeh ; Vivien Darko ; Yskert von Kodolitsch ; Stephan Willems
• 关键词：Marfan syndrome ; Sudden cardiac death ; Natriuretic peptide ; Cardiomyopathy ; Ventricular arrhythmia
• 刊名：International Journal of Cardiology
• 出版年：2013
• 出版时间：10 September, 2013
• 年：2013
• 卷：167
• 期：6
• 页码：2539-2545
• 全文大小：287 K

文摘

Background

Marfan syndrome (MFS) is a variable, autosomal-dominant disorder of the connective tissue. In MFS serious ventricular arrhythmias and sudden cardiac death (SCD) can occur. The aim of this prospective study was to reveal underlying risk factors and to prospectively investigate the association between MFS and SCD in a long-term follow-up.

Methods

77 patients with MFS were included. At baseline serum N-terminal pro-brain natriuretic peptide (NT-proBNP), transthoracic echocardiogram, 12-lead resting ECG, signal-averaged ECG (SAECG) and a 24-h Holter ECG with time- and frequency domain analyses were performed. The primary composite endpoint was defined as SCD, ventricular tachycardia (VT), ventricular fibrillation (VF) or arrhythmogenic syncope.

Results

The median follow-up (FU) time was 868 days. Among all risk stratification parameters, NT-proBNP remained the exclusive predictor (hazard ratio [HR]: 2.34, 95 % confidence interval [CI]: 1.1 to 4.62, p = 0.01) for the composite endpoint. With an optimal cut©\off point at 214.3 pg/ml NT-proBNP predicted the composite primary endpoint accurately (AUC 0.936, p = 0.00046, sensitivity 100 % , specificity 79.0 % ). During FU, seven patients of Group 2 (NT-proBNP ¡Ý 214.3 pg/ml) reached the composite endpoint and 2 of these patients died due to SCD. In five patients, sustained VT was documented. All patients with a NT-proBNP < 214.3 pg/ml (Group 1) experienced no events. Group 2 patients had a significantly higher risk of experiencing the composite endpoint (logrank-test, p < 0.001).

Conclusions

In contrast to non-invasive electrocardiographic parameter, NT-proBNP independently predicts adverse arrhythmogenic events in patients with MFS.